Indegene Ltd (NSE: INDGN, BSE: 544172) is a Bengaluru, Karnataka-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹14,840 Cr, it ranks #466 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 10 in Life Sciences Tools and Services. At ₹648.00 (as of 19 Nov 2026), the share price is 4.3% below its 52-week high of ₹677.00 and 56.5% above its 52-week low of ₹414.00. The share price is up 26.1% over one year and up 14.6% over three months.
| Current Price | ₹648.00 |
|---|---|
| Market Cap | ₹14,840 Cr |
| NSE Symbol | INDGN |
| BSE Code | 544172 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 40.2 |
| Return on Equity | 13.94% |
| Return on Assets | 7.82% |
| 52-Week Range | ₹414.00 – ₹677.00 |
| 1-Year Price Change | +26.1% |
| 3-Month Price Change | +14.6% |
| Beta (1Y) | 0.38 |
| Dividend Yield | 0.34% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.indegene.com |
| Revenue | ₹1,122 Cr |
|---|---|
| Net Profit | ₹112 Cr |
| Net Margin | 10.0% |
| EPS (Basic) | ₹4.67 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indegene Ltd reported revenue of ₹1,122 Cr in Q2 FY27, up 39.6% from ₹804 Cr in Q2 FY26 and up 5.6% from ₹1,063 Cr in Q1 FY27. It posted a net profit of ₹112 Cr for the quarter, against a net profit of ₹102 Cr in Q2 FY26 (up 10.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹756 Cr (Q4 FY25) to ₹1,122 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,122 Cr | ₹112 Cr | 10.0% |
| Q1 FY27 | ₹1,063 Cr | ₹116 Cr | 10.9% |
| Q4 FY26 | ₹1,003 Cr | ₹80 Cr | 7.9% |
| Q3 FY26 | ₹942 Cr | ₹103 Cr | 10.9% |
| Q2 FY26 | ₹804 Cr | ₹102 Cr | 12.7% |
| Q1 FY26 | ₹761 Cr | ₹116 Cr | 15.3% |
| Q4 FY25 | ₹756 Cr | ₹118 Cr | 15.6% |
Consolidated figures (₹ crore, XBRL filings).
Indegene Ltd reports no promoter group in its shareholding filing for Sept 2026. Delivery averaged 60.2% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
1. Enterprise Medical Solutions-This segment offers enterprise medical solutions, including creation and review of medical content, medical communication review, pharmacovigilance, and other safety services, as well as labelling, regulatory submissions, and pricing and market access services. 2. Enterprise Commercial Solutions-This segment develops, deploys, and measures sales and marketing activities, including generation of marketing and promotional content. 3. Others-NA 4. Segment Adjustment-NA
1. Enterprise Medical Solutions-26.5% 2. Others-3.4% 3. Enterprise Commercial Solutions (Incl. Omnichannel Activation)-70.1%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,840 Cr | 40.2 | 13.94% | ₹1,122 Cr | +26.1% |
| Suven Life Sciences Ltd. | ₹7,951 Cr | n/m | -78.80% | ₹1 Cr | +51.8% |
| Vimta Labs Ltd | ₹2,259 Cr | 29.5 | 18.55% | ₹112 Cr | -26.8% |
| Tarsons Products Limited | ₹1,730 Cr | 114.9 | 2.26% | ₹124 Cr | +25.7% |
| Brooks Laboratories Ltd. | ₹198 Cr | 7.9 | 22.28% | ₹19 Cr | -34.2% |
| Bilcare Ltd. | ₹194 Cr | 108.3 | -5.21% | — | — |
| Jeevan Scientific Technology Ltd | ₹176 Cr | 129.4 | 1.68% | — | +42.3% |
| Vivo Bio Tech Ltd. | ₹37 Cr | n/m | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹26 Cr | n/m | -68.79% | — | -45.3% |
Listed by market capitalisation. Ratios are shown for context only.
Indegene Ltd is trading at ₹648.00, with a market capitalisation of ₹14,840 Cr.
Indegene Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Indegene Ltd has a P/E of 40.2 and a return on equity of 13.94%.
Indegene Ltd is listed on the NSE under the symbol INDGN and on the BSE under the scrip code 544172.
Indegene Ltd's share price is up 26.1% over one year and up 14.6% over three months. Its 52-week range is ₹414.00 to ₹677.00.
In Q2 FY27, Indegene Ltd reported revenue of ₹1,122 Cr and net profit of ₹112 Cr, with basic EPS of ₹4.67 (consolidated, parsed from the company's exchange filing).
Indegene Ltd reported revenue of ₹1,122 Cr in Q2 FY27, up 39.6% from ₹804 Cr in Q2 FY26 and up 5.6% from ₹1,063 Cr in Q1 FY27.
Indegene Ltd reports no promoter group in its shareholding filing for Sept 2026.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.